Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
0.916
-0.044 (-4.54%)
Nov 20, 2024, 4:00 PM EST - Market closed
Cytosorbents Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 37.74 | 36.35 | 34.69 | 43.17 | 41 | 24.95 | Upgrade
|
| Revenue | 37.74 | 36.35 | 34.69 | 43.17 | 41 | 24.95 | Upgrade
|
| Revenue Growth (YoY) | 1.80% | 4.79% | -19.64% | 5.27% | 64.35% | 10.87% | Upgrade
|
| Cost of Revenue | 14.07 | 13.96 | 13.96 | 11.05 | 11.05 | 7.36 | Upgrade
|
| Gross Profit | 23.67 | 22.39 | 20.73 | 32.12 | 29.95 | 17.59 | Upgrade
|
| Selling, General & Admin | 35.26 | 36.94 | 36.5 | 38.48 | 31.51 | 24.47 | Upgrade
|
| Research & Development | 9.72 | 15.73 | 15.12 | 16.38 | 8.81 | 12.09 | Upgrade
|
| Operating Expenses | 44.97 | 52.67 | 51.62 | 54.86 | 40.32 | 36.56 | Upgrade
|
| Operating Income | -21.31 | -30.27 | -30.89 | -22.74 | -10.37 | -18.97 | Upgrade
|
| Interest Expense | -0.83 | -0.16 | - | - | -1.2 | -1.03 | Upgrade
|
| Interest & Investment Income | - | - | 0.13 | 0.03 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 3.36 | 1.95 | -2.45 | -2.58 | 2.61 | -0.35 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.06 | 0.1 | -0.07 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -18.71 | -28.39 | -33.27 | -25.29 | -8.96 | -20.36 | Upgrade
|
| Asset Writedown | -0.49 | -0.66 | -0.64 | - | - | - | Upgrade
|
| Legal Settlements | -0.28 | -0.28 | - | - | - | - | Upgrade
|
| Pretax Income | -19.48 | -29.32 | -33.91 | -25.29 | -8.96 | -20.36 | Upgrade
|
| Income Tax Expense | -0.81 | -0.81 | -1.09 | -0.74 | -1.13 | -1.09 | Upgrade
|
| Net Income | -18.67 | -28.51 | -32.81 | -24.56 | -7.84 | -19.27 | Upgrade
|
| Net Income to Common | -18.67 | -28.51 | -32.81 | -24.56 | -7.84 | -19.27 | Upgrade
|
| Shares Outstanding (Basic) | 52 | 45 | 44 | 43 | 39 | 32 | Upgrade
|
| Shares Outstanding (Diluted) | 52 | 45 | 44 | 43 | 39 | 32 | Upgrade
|
| Shares Change (YoY) | 19.27% | 2.49% | 0.49% | 11.70% | 20.35% | 5.00% | Upgrade
|
| EPS (Basic) | -0.36 | -0.64 | -0.75 | -0.57 | -0.20 | -0.60 | Upgrade
|
| EPS (Diluted) | -0.36 | -0.64 | -0.75 | -0.57 | -0.20 | -0.60 | Upgrade
|
| Free Cash Flow | -18.8 | -22.19 | -34.32 | -17.65 | -6.32 | -17.46 | Upgrade
|
| Free Cash Flow Per Share | -0.36 | -0.50 | -0.79 | -0.41 | -0.16 | -0.54 | Upgrade
|
| Gross Margin | 62.71% | 61.60% | 59.77% | 74.41% | 73.05% | 70.48% | Upgrade
|
| Operating Margin | -56.46% | -83.28% | -89.04% | -52.69% | -25.29% | -76.05% | Upgrade
|
| Profit Margin | -49.47% | -78.43% | -94.59% | -56.89% | -19.11% | -77.22% | Upgrade
|
| Free Cash Flow Margin | -49.82% | -61.06% | -98.94% | -40.88% | -15.42% | -69.97% | Upgrade
|
| EBITDA | -19.73 | -28.81 | -30 | -22.01 | -9.71 | -18.39 | Upgrade
|
| EBITDA Margin | -52.29% | -79.26% | -86.49% | -51.00% | -23.68% | -73.72% | Upgrade
|
| D&A For EBITDA | 1.58 | 1.46 | 0.88 | 0.73 | 0.66 | 0.58 | Upgrade
|
| EBIT | -21.31 | -30.27 | -30.89 | -22.74 | -10.37 | -18.97 | Upgrade
|
| EBIT Margin | -56.46% | -83.28% | -89.04% | -52.69% | -25.29% | -76.05% | Upgrade
|
| Revenue as Reported | 37.74 | 36.35 | 34.69 | 43.17 | 41 | 24.95 | Upgrade
|
| Advertising Expenses | - | 0.25 | 0.58 | 0.62 | 0.29 | 0.31 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.